A modified approach of port-access lymphadectomy for locally advanced non-small cell lung cancer: A single center experience
10.11817/j.issn.1672-7347.2021.200065
- VernacularTitle:一种局部晚期非小细胞肺癌微创淋巴结清扫的改良术式 ——单中心经验
- Author:
Sichuang TAN
1
;
Yan HU
;
Muyun PENG
;
Qi HUANG
;
Qikang HU
;
Fenglei YU
Author Information
1. 中南大学湘雅二医院胸外科,长沙410005
- Keywords:
systematic mediastinal lymph node dissection;
video-assisted thoracic surgery;
non-small cell lung cancer
- From:
Journal of Central South University(Medical Sciences)
2021;46(11):1227-1232
- CountryChina
- Language:Chinese
-
Abstract:
Objective: Systematic nodal dissection (SND) is an important component of locally advanced non-small cell lung cancer (NSCLC), but modification of this procedure is rarely reported. In this paper, we reported a modified technique of systematic mediastinal lymph node dissection (MLND) of operable lung cancer by video-assisted thoracic surgery (VATS). Parallel upward dissection (the PUD technique) was named due to this modification and the efficacy of the PUD technique was evaluated as well.Methods: We summarized the tips of the PUD technique and its version was updated in surgical aspect. The design and procedure sequence of the PUD technique were introduced in detail as well as its pros and cons. A retrospective study was performed on 998 cases of locally advanced NSCLC which accepted the PUD procedure in Department of Thoracic Surgery, Second Xiangya Hospital, Central South University, from 2012 to 2020. The perioperative mortality and the incidence of general and serious complications (such as recurrent laryngeal nerve injury, bronchopleural fistula) were analyzed. Results: All the 998 cases were operated successfully with the PUD technique and few post-operation complications were found. There was no perioperative mortality and severe complication such as recurrent laryngeal nerve injury and bronchopleural fistula. Conclusion:The PUD technique is safe and convenient and it can be a good supplement to the existing surgical techniques for locally advanced lung cancer.
